KCAS Bio is excited to announce our participation in several key conferences throughout the world. These events present invaluable opportunities for collaboration, innovation, and the sharing of industry insights. As a leading provider of bioanalytical services, KCAS Bio is committed to engaging with thought leaders, scientists, and professionals worldwide to…

In both preclinical and clinical studies, evaluating immunogenicity—an immune system’s response to a foreign substance—is a critical factor. Anti-drug antibody (ADA) assays play a pivotal role in this evaluation, helping researchers and pharmaceutical companies determine how the immune system reacts to therapeutic drugs. But what exactly is immunogenicity? Simply put,…

The Role of Pharmacokinetics (PK) in Drug R&D Pharmacokinetics (PK) is defined as the study of the fate of a new therapeutic entity (NTE) after it is administered into the body of animals or humans. It involves understanding how the drug is absorbed, distributed, metabolized, and eliminated (ADME). Essentially, PK…

The exploration of Targeted Protein Degraders (TPD) as a therapeutic modality began over twenty years ago. Since then, research and development in this field have steadily advanced. Starting in 2019, rationally designed small molecule TPDs entered clinical trials. This innovative therapeutic modality utilizes the cells’ endogenous protein degradation machinery to…

Preclinical formulation analysis supports toxicity studies before and after the investigational new drug application (IND). Multiple analytical studies support drug development progression beyond the IND stage. KCAS Bio performs analytical studies for a variety of clients. How Does KCAS Bio Perform Preclinical Formulation Analysis? KCAS Bio has completed numerous studies…

Cell and Gene Therapies (CGTs) are types of treatment that uses cellular or genetic material with the goal of treating a disease or a disordered. Often it can be a combination of cell and gene therapies, which is the case for Chimeric antigen receptor T cells (CAR T-Cells). There are…

In today’s drug development efforts, Research and Development has increasingly expanded to include multi-country strategies. Over time, pharmaceutical and biotech companies have made substantial impact on economies where development work is conducted, and some countries have developed strategies (i.e. Australia) to attract this lucrative market via financial incentives and offering…

Spectral flow cytometry and the growing array of commercially available fluorophores have led to the development of increasingly complex immunophenotyping panels.  Generating robust data depends not only on a strong panel design but also on the use of appropriate reference controls and a solid understanding of spectral unmixing principles. …

The world of medicine relies heavily on innovation, and Contract Research Organizations (CROs) are key players behind the scenes. But what exactly is a CRO, and why are these organizations so crucial to the development of new therapies and medical advancements? Let’s explore what CROs do and why they’re vital…

The Rise of Immune Cell Therapies and the Importance of Cell Profiling by Flow Cytometry Immunotherapy is revolutionizing patient care, both in traditional oncology applications as well as in autoimmune indications. The complex mechanism of action based on the enhancement or targeted suppression of immune responses is fraught with challenges;…

2020 was an odd year for everyone. In what felt like just days, it seemed everything had changed and the rules were being rewritten almost daily about how we would all be engaging with one another. We went from racking up travel, hotel stays and airmiles while visiting our customers…

The age of therapeutic conjugation is upon us! Bioanalysis for support of next generation Antibody Drug Conjugates (ADCs) and Antibody siRNA Conjugates (ARCs) have exploded recently due to the efficacy and safety that these therapies offer for immuno-oncology, rare diseases, vaccines and potentially many other diseases. Recently, we have seen…